Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The biological response to treatment with tamoxifen in the preoperative situation is studying
in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +.
The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of
TAM will be studied.